Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2(+):ERα(−) breast cancer

Human Epidermal Growth Factor Receptor 2-positive (HER2(+)) breast cancer (BC) is a highly aggressive disease commonly treated with chemotherapy and anti-HER2 drugs, including trastuzumab. There is currently no way to predict which HER2(+) BC patients will benefit from these treatments. Previous pro...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Liu, Jeff C., Voisin, Veronique, Bader, Gary D., Deng, Tao, Pusztai, Lajos, Symmans, William Fraser, Esteva, Francisco J., Egan, Sean E., Zacksenhaus, Eldad
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: National Academy of Sciences 2012
Pynciau:
Biological Sciences
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3326451/
https://ncbi.nlm.nih.gov/pubmed/22460789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1201105109
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg